These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26727000)

  • 1. Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.
    Pinazo MJ; Posada Ede J; Izquierdo L; Tassies D; Marques AF; de Lazzari E; Aldasoro E; Muñoz J; Abras A; Tebar S; Gallego M; de Almeida IC; Reverter JC; Gascon J
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004269. PubMed ID: 26727000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercoagulability biomarkers in Trypanosoma cruzi -infected patients.
    Pinazo MJ; Tàssies D; Muñoz J; Fisa R; Posada Ede J; Monteagudo J; Ayala E; Gállego M; Reverter JC; Gascon J
    Thromb Haemost; 2011 Oct; 106(4):617-23. PubMed ID: 21866301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.
    Fernández-Villegas A; Pinazo MJ; Marañón C; Thomas MC; Posada E; Carrilero B; Segovia M; Gascon J; López MC
    BMC Infect Dis; 2011 Jul; 11():206. PubMed ID: 21801456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal follow up of serological response in children treated for Chagas disease.
    Moscatelli G; Moroni S; García Bournissen F; González N; Ballering G; Schijman A; Corral R; Bisio M; Freilij H; Altcheh J
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007668. PubMed ID: 31465522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host-Derived Molecules as Novel Chagas Disease Biomarkers: Hypercoagulability Markers in Plasma.
    Alonso-Padilla J; Tassies D; Cortes-Serra N; Gascon J; Reverter JC; Pinazo MJ
    Methods Mol Biol; 2019; 1955():275-286. PubMed ID: 30868535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial.
    Torrico F; Gascon J; Ortiz L; Alonso-Vega C; Pinazo MJ; Schijman A; Almeida IC; Alves F; Strub-Wourgaft N; Ribeiro I;
    Lancet Infect Dis; 2018 Apr; 18(4):419-430. PubMed ID: 29352704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country.
    Murcia L; Carrilero B; Muñoz MJ; Iborra MA; Segovia M
    J Antimicrob Chemother; 2010 Aug; 65(8):1759-64. PubMed ID: 20542903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
    Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
    Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.
    Vallejo A; Monge-Maillo B; Gutiérrez C; Norman FF; López-Vélez R; Pérez-Molina JA
    Acta Trop; 2016 Dec; 164():117-124. PubMed ID: 27619190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of parasitological cure in children infected with Trypanosoma cruzi using a novel multiplex serological approach: an observational, retrospective cohort study.
    Jurado Medina L; Chassaing E; Ballering G; Gonzalez N; Marqué L; Liehl P; Pottel H; de Boer J; Chatelain E; Zrein M; Altcheh J
    Lancet Infect Dis; 2021 Aug; 21(8):1141-1150. PubMed ID: 33836157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease.
    Viotti R; Vigliano C; Alvarez MG; Lococo B; Petti M; Bertocchi G; Armenti A; De Rissio AM; Cooley G; Tarleton R; Laucella S
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1314. PubMed ID: 21909451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.
    Perez-Mazliah DE; Alvarez MG; Cooley G; Lococo BE; Bertocchi G; Petti M; Albareda MC; Armenti AH; Tarleton RL; Laucella SA; Viotti R
    J Antimicrob Chemother; 2013 Feb; 68(2):424-37. PubMed ID: 23104493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina.
    Niborski LL; Grippo V; Lafón SO; Levitus G; García-Bournissen F; Ramirez JC; Burgos JM; Bisio M; Juiz NA; Ayala V; Coppede M; Herrera V; López C; Contreras A; Gómez KA; Elean JC; Mujica HD; Schijman AG; Levin MJ; Longhi SA
    Mem Inst Oswaldo Cruz; 2016 May; 111(6):365-71. PubMed ID: 27223650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.
    Machado-de-Assis GF; Silva AR; Do Bem VA; Bahia MT; Martins-Filho OA; Dias JC; Albajar-Viñas P; Torres RM; Lana M
    Clin Vaccine Immunol; 2012 Aug; 19(8):1283-91. PubMed ID: 22739694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis.
    Pérez-Molina JA; Pérez-Ayala A; Moreno S; Fernández-González MC; Zamora J; López-Velez R
    J Antimicrob Chemother; 2009 Dec; 64(6):1139-47. PubMed ID: 19819909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter epidemiological and clinical study on imported Chagas diseases in Alicante, Spain.
    Ramos JM; Torrús D; Amador C; Jover F; Pérez-Chacón F; Ponce Y; Arjona FJ; Caro E; Martínez-Peinado C; Gallegos I; Cuadrado JM; Tello A; Gutiérrez F
    Pathog Glob Health; 2012 Oct; 106(6):340-5. PubMed ID: 23182138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 12-mer repetitive antigenic epitope from Trypanosoma cruzi is a potential marker of therapeutic efficacy in chronic Chagas' disease.
    Fernandez-Villegas A; Thomas MC; Carrilero B; Lasso P; Egui A; Murcia L; Segovia M; Alonso C; López MC
    J Antimicrob Chemother; 2016 Jul; 71(7):2005-9. PubMed ID: 27073267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.